{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-008773","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2026-08-13T21:21:36+00:00","discovered_at":"2026-08-13T21:22:00.383669+00:00","generated_at":"2026-08-13T21:22:12.548212+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"NeOnc discusses NEO100-01 Phase 2a results; no data in filing excerpt","bullets":["Hosted investor call on Aug 12, 2026 to discuss Phase 2a top-line results of NEO100-01 in recurrent IDH1 mutant high-grade glioma.","Participants included CEO Amir Heshmatpour, CFO Keithly Garnett, CSO Thomas Chen, and Chief Clinical Officer Josh Neman.","Provided transcript does not include specific efficacy or safety data; only call introduction is in the exhibit."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-008773","json":"https://secwatch.observer/filing/0001829126-26-008773.json","markdown":"https://secwatch.observer/filing/0001829126-26-008773.md","text":"https://secwatch.observer/filing/0001829126-26-008773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626008773/0001829126-26-008773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626008773/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T21:22:12.548212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}